Cargando…

Long-term outcomes of rituximab, temozolomide and high-dose methotrexate without consolidation therapy for lymphoma involving the CNS

AIM: To describe the long-term outcomes of patients with lymphoma in the CNS treated with rituximab, temozolomide and high-dose methotrexate without consolidation therapy. PATIENTS & METHODS: A retrospective cohort study of 46 consecutive patients with primary CNS lymphoma (PCNSL, 27 patients) o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nagle, Sarah J, Shah, Nirav N, Ganetsky, Alex, Landsburg, Daniel J, Nasta, Sunita D, Mato, Anthony, Schuster, Stephen J, Reshef, Ran, Tsai, Donald E, Svoboda, Jakub
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171986/ https://www.ncbi.nlm.nih.gov/pubmed/30302232 http://dx.doi.org/10.2217/ijh-2017-0020

Ejemplares similares

The role of FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma
por: Nagle, Sarah J, et al.
Publicado: (2015)

Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas
por: Svoboda, Jakub, et al.
Publicado: (2020)

Safety and Efficacy of Sars-Cov-2 Vaccines in Hodgkin Lymphoma Patients Receiving PD-1 Inhibitors
por: Svoboda, Jakub, et al.
Publicado: (2021)

R-CHOP intensification with mid-cycle methotrexate and consolidating AraC/TT with BCNU/aHSCT in primary aggressive lymphoma with CNS involvement
por: Steinhardt, Maximilian J., et al.
Publicado: (2021)

Salvage radiotherapy for relapsed/refractory non‐Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy
por: Yegya-Raman, Nikhil, et al.
Publicado: (2023)

P1160: METHOTREXATE IN COMBINATION WITH IBRUTINIB, THIOTEPA, RITUXIMAB (R-MTO) FOLLOWED BY AUTOLOGOUS STEM-CELL TRANSPLANT FOR PRIMARY CNS LYMPHOMA
por: Xing, LI-Jie, et al.
Publicado: (2023)

High‐dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China
por: Chen, Cui, et al.
Publicado: (2019)

High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials
por: Yu, Junyao, et al.
Publicado: (2021)

Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma
por: Buchegger, Franz, et al.
Publicado: (2011)

Is more better? Increased doses of high dose methotrexate and addition of rituximab is associated with improved outcomes in a large primary CNS lymphoma cohort
por: Yerram, Prakirthi, et al.
Publicado: (2023)

Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C
por: Mishima, Kazuhiko, et al.
Publicado: (2022)

CD 5+ Peripheral B Cell Lymphoma With Transformation to CD 5+ Diffuse Large B Cell Lymphoma in the CNS: A Case Report Treated With Rituximab, High Dose Methotrexate, Cytarabine, and Intrathecal Methotrexate
por: Uczkowski, Dariusz, et al.
Publicado: (2022)

Corrigendum to: Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C
Publicado: (2023)

Rituximab/methotrexate: Lack of efficacy: case report
Publicado: (2022)

Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma
por: Modelevsky, Lisa, et al.
Publicado: (2018)

Non-Myeloablative Chemotherapy as Consolidation Strategy After High-Dose Methotrexate-Based Chemoimmunotherapy in Patients With Primary CNS Lymphoma: A Retrospective Single Center Study in China
por: Sun, Xuefei, et al.
Publicado: (2022)

Combination Therapy with Rituximab and Temozolomide for Recurrent and Refractory Primary Central Nervous System Lymphoma
por: Murakami, Mineko, et al.
Publicado: (2011)

Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma
por: Yamshon, Samuel, et al.
Publicado: (2023)

Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas
por: Ferreri, A J M, et al.
Publicado: (2004)

High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)
por: Fritsch, K, et al.
Publicado: (2017)

Intravascular CNS lymphoma: Successful therapy using high-dose methotrexate-based polychemotherapy
por: Kebir, Sied, et al.
Publicado: (2012)

Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: an LOC network study
por: Lesueur, Paul, et al.
Publicado: (2022)

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
por: Mato, Anthony R., et al.
Publicado: (2018)

A systematic review and meta-analysis of rituximab combined with methotrexate versus methotrexate alone in the treatment of rheumatoid arthritis
por: Wang, Zhao, et al.
Publicado: (2020)

Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort
por: Bowers, Jackson T., et al.
Publicado: (2023)

Methotrexate/prednisone/rituximab: COVID-19 pneumonia: 3 case reports
Publicado: (2021)

Methotrexate/prednisolone/rituximab: COVID-19 pneumonia: 2 case reports
Publicado: (2021)

Methotrexate Induced Lung Injury in a Patient with Primary CNS Lymphoma: a Case Report
por: Chhabra, Puneet, et al.
Publicado: (2012)

Incorporating Cystatin C to Predict Methotrexate Elimination in Patients with CNS Lymphoma and Suspicious Renal Function
por: Barreto, Jason N., et al.
Publicado: (2018)

Lenalidomide and Temozolomide Combination in a Very Elderly Patient with CNS Relapse of Diffuse Large B-Cell Lymphoma
por: Cencini, Emanuele, et al.
Publicado: (2017)

Hodgkin lymphoma patients have an increased incidence of idiopathic acquired aplastic anemia
por: Linaburg, Taylor, et al.
Publicado: (2019)

Advancing the management of double hit lymphoma
por: Landsburg, Daniel J.
Publicado: (2017)

Effect of Intravitreal Methotrexate and Rituximab on Interleukin-10 Levels in Aqueous Humor of Treated Eyes with Vitreoretinal Lymphoma
por: Raja, Harish, et al.
Publicado: (2013)

Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma
por: Zhao, Defeng, et al.
Publicado: (2014)

Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma
por: Sun, Xuefei, et al.
Publicado: (2017)

Use of rituximab, temozolomide, and radiation in recurrent and refractory primary central nervous system lymphoma in the Philippines: a retrospective analysis
por: Batara, Julette Marie F, et al.
Publicado: (2022)

Salvage chemotherapy with R-BAD (rituximab, bendamustine, cytarabine, and dexamethasone) for the treatment of relapsed primary CNS lymphoma
por: Cho, Min-Seok, et al.
Publicado: (2016)

Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse
por: Bobillo, Sabela, et al.
Publicado: (2021)

ML-08 THE ROLE OF MAINTENANCE HIGH-DOSE METHOTREXATE CHEMOTHERAPY IN ELDERLY PRIMARY CNS LYMPHOMA PATIENTS
por: Mishima, Kazuhiko, et al.
Publicado: (2019)

High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma
por: Ong, Shin Yeu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o87uhcguqbckh4q4ln0d6sor50